Highbridge

Letter to Shareholders and Corporate Update

Retrieved on: 
Monday, September 11, 2023
Highbridge, Letter, Partnership, Therapy, Marketing, API, Woman, Hospira, Fertilisation, Sale, MITRA, EUR, CDMO, CEST, Brussels Stock Exchange, Menopause, White box, Management, Financial services, Pharmaceutical industry, Estetrol

Liege, Belgium, 11 September 2023 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, (the “Company” or “Mithra”), today published a Letter to Shareholders and Corporate Update from Chief Executive Officer, Dr. David Horn Solomon.

Key Points: 
  • Liege, Belgium, 11 September 2023 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, (the “Company” or “Mithra”), today published a Letter to Shareholders and Corporate Update from Chief Executive Officer, Dr. David Horn Solomon.
  • We raised EUR 20 million in a successful equity financing, with potential for up to an additional EUR 45 million in equity.
  • I hope that you will agree that these achievements are significant and consistent with the strategy we set forth in our shareholder letter in May.
  • Mithra’s executive leadership is working closely and in lock-step with our Board of Directors to execute on our strategy.

Santhera Announces Closing of Exclusive North America License Agreement with Catalyst Pharmaceuticals for Vamorolone

Retrieved on: 
Wednesday, July 19, 2023
Highbridge Capital Management, Treasury, Vamorolone, Catalyst Pharmaceuticals, Highbridge, Partnership, Duchenne muscular dystrophy, European Medicines Agency, Sale, EMA, U.S. FDA, Acquisition, Patient, PDUFA, Hart–Scott–Rodino Antitrust Improvements Act, FDA, Pharmaceutical industry, Security (finance), DMD, Catalysis

53 LR

Key Points: 
  • 53 LR
    Pratteln, Switzerland, July 19, 2023 – Santhera Pharmaceuticals (SIX: SANN) announces the closing of the exclusive license agreement for vamorolone in North America (NA) with Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX), announced on June 20, 2023 [1].
  • The license agreement grants Catalyst commercialization rights in North America (NA) for vamorolone in Duchenne muscular dystrophy (DMD) and all potential future indications for a total consideration to Santhera of up to USD 231 million plus royalty payments from product sales.
  • Outside the core European countries where Santhera will commercialize vamorolone directly, the Company seeks partnerships and has granted Catalyst a right of first negotiation in partnering discussions.
  • Closing of the transaction was subject to customary closing conditions and expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.

Destination Tomorrow Announces Annual Bronx Pride Week from June 13 to June 17

Retrieved on: 
Monday, June 12, 2023
Park, Black Trans Femmes in the Arts, Grand Concourse, Highbridge, Partnership, Food, Housing, The arts, Transgender, Hostos Center for the Arts & Culture, TD, Amsterdam, Clothing, Work, Black box, Aja, Toronto-Dominion Bank, RuPaul, Gender, ...Continued, HBO Max, FX, Council, Queer, South Bronx, San Francisco Gay Men's Chorus, Westchester, Health, House, Nightclub, Tourism, Pride, The Bronx, Chorus

BRONX, N.Y., June 12, 2023 /PRNewswire/ -- The LGBTQ+ grassroots organization Destination Tomorrow will host its annual Bronx Pride Week in New York from June 13 to June 17. This year's theme, "Investing in Us," celebrates LGBTQ+ individuals and sheds light on the programs, resources and allyship the community needs.

Key Points: 
  • BRONX, N.Y., June 12, 2023 /PRNewswire/ -- The LGBTQ+ grassroots organization Destination Tomorrow will host its annual Bronx Pride Week in New York from June 13 to June 17.
  • Bronx Pride Week arrives amid a political landscape violating the rights and freedoms of the LGBTQ+ community.
  • The center hopes to see everyone in the Bronx to celebrate Pride and show their support for these individuals.
  • The annual Bronx Pride Festival, hosted by Aja from RuPaul's Drag Race and Jack Gorgeous Gucci from FX's Pose and HBO Max's Legendary, will conclude the week of celebration.

Mithra - Letter to Shareholders and Corporate Update

Retrieved on: 
Thursday, May 25, 2023
Highbridge, Gedeon Richter, Letter, Mayo Clinic, Drawing, Endometrium, Therapy, Arthralgia, File, Marketing, Birth, Silence Therapeutics, NDA, BL 2.75-inch mountain gun, Ageing, Woman, Quality of life, Hospira, Research, Negotiation, Attention, Brain, DRSP, Hot, GSI, MITRA, Incidence, Communication, EUR, Dementia, CDMO, System, Patient, CEST, Estrogen, Brussels Stock Exchange, Menopause, Liver, Growth, Mortality, MAA, FDA, Zealand Pharma, Management, Risk management, Pharmaceutical industry, Medical device, Security (finance), Mithra, Estetrol, White box

Donesta® filing rescheduled for H2 2023 - still expecting U.S. approval in H1 2024

Key Points: 
  • Donesta® filing rescheduled for H2 2023 - still expecting U.S. approval in H1 2024
    Liege, Belgium, 25 May 2023 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, (the "Company" or "Mithra"), today published a Corporate Update and Letter to Shareholders from recently appointed Chief Executive Officer, Dr. David Horn Solomon.
  • I accepted the role because my analysis revealed strong fundamentals and tremendous potential to create significant value for Mithra shareholders.
  • Collectively, the Mithra leadership understands that our ability to create value for our shareholders is a primary directive that goes hand in hand with developing medicines for women.
  • I look forward to continuing with increased transparency and regular communications to providing updates on our progress to you, our shareholders.

Gamida Cell Announces Closing of $25 Million Financing With Highbridge

Retrieved on: 
Monday, December 12, 2022
Research, Hospitals, Clinical Trials, Stem Cells, Biotechnology, Health, Pharmaceutical, Science, Oncology, B cell, Therapy, Security (finance), NAM, Lymphatic system, Prescription Drug User Fee Act, NK, Breakthrough therapy, Immunotherapy, Hospital, BLA, Patient, Hematology, Graft-versus-host disease, Highbridge Capital Management, Cell, FDA, COVID-19, Bone marrow, Trial of the century, Clinical trial, Safety, Risk, Priority review, ADCC, Mortality, Infection, PDUFA, Highbridge, Phenotype, Vaccine, Pharmaceutical industry, EU

Omidubicel has the potential to address the unmet need for patients with hematologic malignancies in need of an allogeneic hematopoietic stem cell transplant, said Abbey Jenkins, CEO of Gamida Cell.

Key Points: 
  • Omidubicel has the potential to address the unmet need for patients with hematologic malignancies in need of an allogeneic hematopoietic stem cell transplant, said Abbey Jenkins, CEO of Gamida Cell.
  • Omidubicel is an advanced cell therapy candidate developed as a potential life-saving allogeneic hematopoietic stem cell (bone marrow) transplant for patients with blood cancers.
  • Gamida Cell is pioneering a diverse immunotherapy pipeline of potentially curative cell therapy candidates for patients with solid tumor and blood cancers and other serious blood diseases.
  • Although Gamida Cells forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Gamida Cell.

FFL Promotes Jonathon Bunt and Karen Winterhof to Partner

Retrieved on: 
Thursday, December 8, 2022
Professional Services, Finance, FFL, Dubilier, Morgan Stanley, Culture, Clayton, Dubilier & Rice, Highbridge, Mentorship, Goldman Sachs, Berkshire Partners, Investment, Growth, Harvard Business School, Elderly care, Friedman Fleischer & Lowe, Management, Financial services, Health care

FFL Partners (FFL), a private equity firm focused on growth investments in Healthcare and Tech-Enabled Services businesses, today announced the promotions of Jonathon (Jon) Bunt and Karen Winterhof to Partner.

Key Points: 
  • FFL Partners (FFL), a private equity firm focused on growth investments in Healthcare and Tech-Enabled Services businesses, today announced the promotions of Jonathon (Jon) Bunt and Karen Winterhof to Partner.
  • Through these promotions, we are thrilled to recognize the invaluable contributions that Jon and Karen have made to our teams success, said Cas Schneller, Managing Partner at FFL.
  • Jon and Karen bring highly complementary experience and skillsets to FFL, and their promotions reflect the continued evolution of talent at FFL, founded 25 years ago, added Chris Harris, Managing Partner.
  • Karen Winterhof joined FFL in 2015 as a Senior Associate and focuses on the firms Healthcare Services investments.

HighBridge Premium™ Signs Distribution Agreement with MOB in Minnesota

Retrieved on: 
Tuesday, December 13, 2022
Beers, Social media, MSO, Highbridge, Radar, Charity (practice), Starters with Mocktales, Sale, Research, Hemp, Stock, Drink, Quality of life, Education, Social responsibility, Marketing, Energy drink, Drug, Engineering

HighBridge has selected MOB Distribution, a Minnesota based company, for exclusive sales and distribution of the HighBridge products.

Key Points: 
  • HighBridge has selected MOB Distribution, a Minnesota based company, for exclusive sales and distribution of the HighBridge products.
  • Adding that adjusting the formulas of the HighBridge products to be compliant with Minnesota Regulations, while continuing the HighBridge principles of great taste and product integrity, took a few months.
  • The first of the HighBridge products are scheduled to hit the shelves in a variety of locations throughout Minnesota this month.
  • HighBridge Premium (The HighBridge Company, LLC) is a Wyoming corporation that, in conjunction with its consulting, lab and marketing partners, develops premium beverages for the recreational legal cannabis and hemp industries.

Santhera Calls Extraordinary General Meeting to Seek Approval for Further Financings

Retrieved on: 
Friday, November 4, 2022
Proxy, EGM, Social Security, Company, Time, DMD, EMA, Mass meeting, Board, Leber's hereditary optic neuropathy, Hotel manager, Vamorolone, European Medicines Agency, Cystic fibrosis, CHF, Public–Private Investment Program for Legacy Assets, FDA, Legislation, Treasury, NDA, LHON, COVID-19, PIPE, MAA, Duchenne muscular dystrophy, ABB, REDI (Execution Management System), Highbridge, Patient, Communication, Security (finance), Animal, Pharmaceutical industry, EU

53 LR

Key Points: 
  • 53 LR
    Pratteln, Switzerland, November 4, 2022 Santhera Pharmaceuticals (SIX: SANN) provides an update on its activities and is calling an Extraordinary General Meeting (EGM), which will be held on November 29, 2022, at 10:30 hrs at the domicile of the Company.
  • At the EGM, Santhera seeks authorization for additional funding to enable continued pipeline development and preparations for the commercialization of vamorolone.
  • As announced earlier, the primary operational focus of Santhera in 2022 continues to be the advancement of the regulatory submissions for vamorolone in the U.S. and the EU towards approval.
  • Santhera still has treasury shares, conditional and authorized capital from past authorizations by shareholders which are available for future placement, subject to market conditions.

Invacare Corporation Announces Additional Draw of Term Loans and Exchange of Existing Convertible Notes

Retrieved on: 
Monday, October 3, 2022
Health, General Health, Highbridge, Securities Act of 1933, Rancho Los Amigos National Rehabilitation Center, Government, Note, Time, Stroke, Chronic obstructive pulmonary disease, Muscular dystrophy, Debt-to-GDP ratio, Private Securities Litigation Reform Act, Rest, Spina bifida, Birth, Invacare, Corporation, COVID-19, Risk, Health, IVC, Cerebral palsy, Sumathi Best Television Current Reporting Award, U.S. Securities and Exchange Commission, Credit, NYSE, Sale, Security (finance), ERP, Forward-looking statement, Multiple sclerosis, Investment, Credit agreements in South Africa, COPD, Annual report, ALS

Invacare Corporation (NYSE:IVC) (Invacare or the company) announced today the consummation of additional draws of an aggregate of $18,500,000 of term loans pursuant to its Credit Agreement with certain funds managed by Highbridge Capital Management LLC (Highbridge).

Key Points: 
  • Invacare Corporation (NYSE:IVC) (Invacare or the company) announced today the consummation of additional draws of an aggregate of $18,500,000 of term loans pursuant to its Credit Agreement with certain funds managed by Highbridge Capital Management LLC (Highbridge).
  • Additional commitments of $19,500,000 remain available under the Amended Highbridge Loan Agreement, subject to the satisfaction of certain conditions set forth therein.
  • The transactions described herein are further described in a Current Report on Form 8-K to be filed with the Securities and Exchange Commission.
  • Invacare Corporation (NYSE:IVC) (Invacare or the company) is a leading manufacturer and distributor in its markets for medical equipment used in non-acute care settings.

Santhera Announces Preliminary 2022 Half-year Financial Results Ahead of Full Report Publication by End of October

Retrieved on: 
Thursday, September 29, 2022
CHF, EBITDA, Company, EBIT, Highbridge, Patient, File, LHON, Vamorolone, VWAP, Leber's hereditary optic neuropathy, DMD, Cystic fibrosis, Communication, Renewable energy, Online gambling, Music, Pharmaceutical industry

The Company plans to publish its 2022 Half-year Report, with an operational progress update, during October 2022.

Key Points: 
  • The Company plans to publish its 2022 Half-year Report, with an operational progress update, during October 2022.
  • Santhera and Highbridge have amended the existing financing arrangement with Santhera that the Company previously announced on June 2, 2022.
  • SIX Exchange Regulation has permitted Santhera to publish its 2022 Half-year Report on October 31, 2022, at the latest.
  • Santhera is in the process of completing the 2022 Half-year Report and the postponement enables Santhera to reflect its new arrangements with Highbridge.